Lupin Q4: Analysts expect 108% PAT growth at Rs 324 cr

Healthcare firm Lupin will announce its fourth quarter (January-March) earnings on Wednesday. Analysts on an average expect the profit after tax to grow by 108.3 percent year-on-year to Rs 324 crore, according to CNBC-TV18 poll.

Revenues are seen going up by 25 percent to Rs 2,406 crore from Rs 1,924 crore Y-o-Y.

Also Read - Lupin operating profit may lag estimates: StarMine

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to jump 46.4 percent Y-o-Y to Rs 546 crore during the quarter, due to exclusivity upside as well as higher utilization at Indore SEZ.

Operating profit margin is expected to show solid growth at 22.7 percent in March quarter as against 19.4 percent Y-o-Y.

Expectations

Its US markets' business boosted by limited competition products such as oral contraceptives (OCs) and others like Tricor generic, Fortamet, Combivir and Geoden.

Tricor generic (cholesterol drug) will see full contribution in March quarter.

Rest of the world will register strong growth due to increased market penetration.

Domestic business would continue to report strong growth, led by Lupin’s focus on chronic therapy